Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)
Trial details
- Registry ID
- NCT02077192
- Phase
- Phase 3
The FDA approved Fostamatinib Disodium (R788) on 17 Apr 2018.
Drug identity checked against registry records
Also recorded as Fostamatinib; R788; R935788
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)NCT02077192 | Rigel Pharmaceuticals | Phase 3 | Completed | 2020-06-02Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2018-04-17Day | Fostamatinib Disodium | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA209299", "applicant_as_listed_by_fda": "RIGEL PHARMS", "brand_names": ["TAVALISSE"], "active_ingredients": ["FOSTAMATINIB DISODIUM"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20180417", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |